Journal of Genetic Disorders & Genetic ReportsISSN: 2327-5790

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Arzu Didem Yalcin Author

didyal@gate.sinica.edu.tw

Subjects of specialization
omalizumab

Affiliation
Department of Internal Medicine, Allergy and Clinical Immunology Unit, Antalya Training and Research Hospital, Antalya 070707, Turkey

Biography

Arzu Didem Yalcin Patel TN belongs to Department of Internal Medicine, Allergy and Clinical Immunology Unit,  intrested in the fieldProtein C; A heterozygous carrier of factor V Leiden and prothrombin G20210A mutation; omalizumab; Anti-IgE; Transplant rejection from SAntalya Training and Research Hospital, Antalya 070707, Turkey

Publications

Letter to Editor Subscription

Anti-Ige (Omalizumab) Improved Trombotic Emboli by Elevating Activated Protein C, Protein S, and Antithrombin III in a Case of Prothrombin G20210A Mutation: Long Term Follow-Up

Author(s):

Arzu Didem Yalcin and Betul Celik

Plasma protein C levels were significantly lower compared to patients without acute rejection at the time of rejection, specifically antibody mediated rejection [1,2]. In a parallel mammer Endothelial Protein C Receptor (EPCR) expression was found higher in tubules and arteries of rejection patients than in control patients [3] and activation of the inflammatory/coagulation cascades has been suggested in the pathogenesis of the rejection.

 view more»

DOI: 10.4172/2327-5790.1000129

Abstract HTML PDF

Google Scholars / Researchers Sites

Explore SciTechnol

GET THE APP